Figure 3.

The CNDAC/vorinostat combination activates Bax and Bak in MV4-11 cells. MV4-11 cells were treated with dimethylsulphoxide (m), 1 × IC₅₀ CNDAC (C), vorinostat (V) or both compounds in a sequential manner (CV). Combination treatment involved 24-h CNDAC pre-treatment followed by 16-h vorinostat treatment. One of the drug treatments was replaced by a drug-free media treatment in the two single-agent controls (m). Cells were then harvested and the resulting lysates used to measure the levels of activated Bax or Bak. Some of the samples were incubated with secondary antibody in the absence of primary antibody (secondary Ab) to assess non-specific binding of the FITC secondary antibody. Results are the average ± s.d. of two independent experiments.